# US 2025/0179122 A1 · Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0179122 A1
- Document ID: US20250179122A1
- Status: Published application
- Kind: A1
- Application number: 19/025,363
- Filed: 2025-01-16
- Published: 2025-06-05
- Earliest claimed: 2007-11-14
- Assignees: Sierra Sciences, Inc.
- Applicants: Sierra Sciences, LLC
- Inventors: William H. Andrews; Christopher A. Foster; Lancer K. Brown; Laura A. Briggs; October Pawlik; Penelope Burke; Federico C.A. Gaeta; Beril Karakas; Jessica Wheeler; Mieczyslaw A. Piatyszek; Munirathnam Chaguturu; Jian Zhang; Tom Kerley; Hamid Mohammadpour
- Web page: https://patentgrep.com/patent/US20250179122A1

## CPC

- C07K 9/003: {Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin}
- C07D 215/06: having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
- C07D 231/22: with aryl radicals attached to ring nitrogen atoms
- C07D 279/02: 1,2-Thiazines; Hydrogenated 1,2-thiazines
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 493/08: Bridged systems
- C07D 498/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07H 17/04: Heterocyclic radicals containing only oxygen as ring hetero atoms
- C12N 15/01: Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Telomerase reverse transcriptase (TERT) expression enhancing compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.

## Claims

### Claim 1

A method for enhancing telomerase reverse transcriptase (TERT) expression in a cell, the method comprising:
contacting the cell with a TERT expression enhancing effective amount of a compound selected from the group consisting of quinolines, pyrazols, fused pyrazols, benzothiazole-triazinones, azoles, benzothiazines, bridged cyclohexanes, naphthofuranones, tetrahydrofuro-oxazolo-pyrimidinols, aza-fluorenes, oxadiazolo-pyrazines, tetrahydro-benzothiophenes, pyrimidinediones, benzofurans, dihydro-triazolo-thiadiazines, benzo-oxazine-diones, dihydro-pyridines, pyrazolo-pyrimidines, hydroxy-pyridinones, benzenesulfonyl-piperidines, benzo-azole, pyridin-2-yl-pyridazines, thieno-triazolo-pyrimidine, hydrazos, pyrazol-1-yl-pyrimidinones, thieno-pyridazinones, thiadiazolamines, pentaaza-indacenes, chromenones, N-phenyl-benzamides, N-phenyl-phenylsulfonamides, diphenylthioureas, and compounds 1312 to 1476 and 1541 to 1557 of Table 1.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound is a quinoline.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the compound is described by one of structures 1001 to 1105 and 1477 to 1482 of Table 1.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the compound is a pyrazol.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the compound is described by one of structures 1106 to 1144 and 1483 to 1485 of Table 1.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the compound is a fused pyrazol.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the compound is described by one of structures 1145 to 1169 and 1486 of Table 1.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the compound is a benzothiazole-triazinone.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the compound is described by structure 1170 of Table 1.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the compound is an azole.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the compound is described by one of structures 1171 to 1208 and 1487 to 1525 of Table 1.

### Claim at position 12

12-64. (canceled)

### Claim 65 (depends on 1)

The method according to claim 1, wherein the proliferative capacity of the cell is increased.

### Claim 66 (depends on 1)

The method according to claim 1, wherein senescence of the cell is delayed.

### Claim at position 15

67-77. (canceled)

### Claim 78

A pharmaceutical composition comprising a tert expression enhancing compound selected from the group consisting of quinolines, pyrazols, fused pyrazols, benzothiazole-triazinones, azoles, benzothiazines, bridged cyclohexanes, naphthofuranones, tetrahydrofuro-oxazolo-pyrimidinols, aza-fluorenes, oxadiazolo-pyrazines, tetrahydro-benzothiophenes, pyrimidinediones, benzofurans, dihydro-triazolo-thiadiazines, benzo-oxazine-diones, dihydro-pyridines, pyrazolo-pyrimidines, hydroxy-pyridinones, benzenesulfonyl-piperidines, benzo-azole, pyridin-2-yl-pyridazines, thieno-triazolo-pyrimidine, hydrazos, pyrazol-1-yl-pyrimidinones, thieno-pyridazinones, thiadiazolamines, pentaaza-indacenes, chromenones, N-phenyl-benzamides, N-phenyl-phenylsulfonamides, diphenylthioureas, and compounds 1312 to 1476 and 1541 to 1557 of Table 1; and a pharmaceutically acceptable carrier.

### Claim 79 (depends on 78)

The composition according to claim 78, wherein the composition is a topical composition.

### Claim 80 (depends on 79)

The composition according to claim 79, wherein the composition further comprises a sunblocking agent.

### Claim 81

A method of screening a compound for enhancing telomerase reverse transcriptase (TERT) expression in a cell, the method comprising:
contacting the cell with the compound and evaluating whether the compound enhances TERT expression in the cell;
wherein the compound is selected from the group consisting of quinolines, pyrazols, fused pyrazols, benzothiazole-triazinones, azoles, benzothiazines, bridged cyclohexanes, naphthofuranones, tetrahydrofuro-oxazolo-pyrimidinols, aza-fluorenes, oxadiazolo-pyrazines, tetrahydro-benzothiophenes, pyrimidinediones, benzofurans, dihydro-triazolo-thiadiazines, benzo-oxazine-diones, dihydro-pyridines, pyrazolo-pyrimidines, hydroxy-pyridinones, benzenesulfonyl-piperidines, benzo-azole, pyridin-2-yl-pyridazines, thieno-triazolo-pyrimidine, hydrazos, pyrazol-1-yl-pyrimidinones, thieno-pyridazinones, thiadiazolamines, pentaaza-indacenes, chromenones, N-phenyl-benzamides, N-phenyl-phenylsulfonamides, diphenylthioureas, and compounds 1312 to 1476 and 1541 to 1557 of Table 1.

### Claim 82 (depends on 78)

The composition according to claim 78, wherein the compound is an azole.

### Claim 83 (depends on 82)

The composition according to claim 82, wherein the compound is described by one of structures 1171 to 1208 and 1487 to 1525 of Table 1.
